n(4)-hydroxycytidine has been researched along with deoxyuridine in 2 studies
| Studies (n(4)-hydroxycytidine) | Trials (n(4)-hydroxycytidine) | Recent Studies (post-2010) (n(4)-hydroxycytidine) | Studies (deoxyuridine) | Trials (deoxyuridine) | Recent Studies (post-2010) (deoxyuridine) |
|---|---|---|---|---|---|
| 42 | 1 | 32 | 2,256 | 22 | 446 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, C; Lewis, P; Warren, S; Waters, MD; Zhang, F | 1 |
| David Ordonez Luna, A; Downs, IL; Kota, KP; Litosh, VA; Panchal, RG; Rubin, SK; Shirsekar, SS; Ward, MD | 1 |
1 review(s) available for n(4)-hydroxycytidine and deoxyuridine
| Article | Year |
|---|---|
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Topics: Amides; Antiviral Agents; COVID-19 Drug Treatment; Cytidine; Deoxyuridine; DNA Damage; Genome, Human; Humans; Hydroxylamines; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2 | 2022 |
1 other study(ies) available for n(4)-hydroxycytidine and deoxyuridine
| Article | Year |
|---|---|
Modification of N-hydroxycytidine yields a novel lead compound exhibiting activity against the Venezuelan equine encephalitis virus.
Topics: Animals; Antimetabolites; Antiviral Agents; Deoxyuridine; Encephalitis Virus, Venezuelan Equine; Horses; Humans; Immunosuppressive Agents | 2023 |